Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-01-10
DOI
10.1002/cpt.1012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections
- (2017) Issam S. Hamadeh et al. Pharmacogenetics and Genomics
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
- (2016) Thomas F. Patterson et al. CLINICAL INFECTIOUS DISEASES
- Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis
- (2016) Lu Chen et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation
- (2016) Gaoqi Xu et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections
- (2016) Fabien Lamoureux et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers
- (2015) Piergiorgio Cojutti et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
- (2014) M. J. Dolton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- CYP2C19Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
- (2014) Aniwaa Owusu Obeng et al. PHARMACOTHERAPY
- Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections
- (2013) T. Wang et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
- (2012) Michael J. Dolton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
- (2012) Wan Beom Park et al. CLINICAL INFECTIOUS DISEASES
- Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
- (2011) Peter F. Troke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis
- (2011) Alan M. Laties et al. CLINICAL THERAPEUTICS
- Pharmacogenomics of the triazole antifungal agent voriconazole
- (2011) Gerd Mikus et al. PHARMACOGENOMICS
- Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
- (2010) Maud Berge et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
- (2010) Hui-Yan Shi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Voriconazole concentrations and outcome of invasive fungal infections
- (2009) S. Miyakis et al. CLINICAL MICROBIOLOGY AND INFECTION
- Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
- (2009) Koki Ueda et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
- (2008) Thomas J. Walsh et al. CLINICAL INFECTIOUS DISEASES
- The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
- (2008) Guo Wang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
- (2008) Johanna Weiss et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes
- (2007) A. Pascual et al. CLINICAL INFECTIOUS DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started